April 12, 2025Regeneron Pharmaceuticals Receives Dupixent Approval in Japan ~1 min.Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) has recently received approval for its drug Dupixent in Japan....
March 16, 2025JIM CRAMER ENCOURAGES INVESTORS TO OWN REGENERON PHARMACEUTICALS INC. ~2 min.In the latest episode of Mad Money, renowned financial expert Jim Cramer expressed his bullish stance on Regeneron Pharmaceuticals Inc. (REGN)....
March 15, 2025Regeneron Pharmaceuticals Inc.: A Promising Investment Opportunity ~2 min.Regeneron Pharmaceuticals Inc....
March 1, 2025Regeneron Pharmaceuticals Inc. Reports Promising Results, Garnering Attention from Investors ~2 min.Regeneron Pharmaceuticals Inc. (REGN) has recently announced positive results from its latest clinical trials, causing a surge in investor interest....
February 26, 2025Regeneron Pharmaceuticals Faces Legal Pressure and Growth Potential, According to Analysts ~2 min.Regeneron Pharmaceuticals, Inc. (REGN) is currently facing mounting pressure on both its sales and legal fronts....
January 4, 2025Regeneron Pharmaceuticals Inc.: A Strong Investment Opportunity for Shareholders ~1 min.Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) has proven to be a successful investment option for shareholders, with a decent 89% return over the last five years....
January 6, 2025Regeneron Pharmaceuticals Inc. Continues to Impress Investors with Strong Financial Performance ~1 min.Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) has reported a remarkable 89% return for its investors over the last five years, according to a recent report by Yahoo Finance....
January 2, 2025Regeneron Pharmaceuticals: An Impressive 89% Return Over the Last Five Years ~2 min.Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) has been a rewarding investment for shareholders, with a solid 89% return over the past five years, according to Yahoo Finance....
January 2, 2025Regeneron Pharmaceuticals Continues to Impress Investors with Strong Returns ~1 min.In the past five years, Regeneron Pharmaceuticals (NASDAQ:REGN) has delivered a solid return of 89%, making it a favorable choice for investors....
January 12, 2025Regeneron Pharmaceuticals Faces Shareholder Class Action Lawsuit ~1 min.Regeneron Pharmaceuticals, Inc., a leading biotechnology company, is currently facing a shareholder class action lawsuit....
